Manila Times Business
Sparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 Diabetes
Clofutriben improved HbA1c and other cardiometabolic parameters in patients with Type 2 diabetes in a 6-week, placebo-controlled, randomized Phase 2 trial Subset of participants with elevated cortisol (EC) risk factors showed numerically greater improvements in glycemic control and lipid parameters, along with benefits on blood pressure and body weight BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, Inc., a targeted cardiometabolic therapeutics company, today announced positiv
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ateneo’s Baterbonia, Adili drown during team building in Aurora
3h ago
Foresight Secures $17.5 Million Strategic Investment from VisionWave at a $34 Million Valuation Post Investment to Advance AI Perception Capabilities for Defense and Security
3h ago
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
3h ago
Rocky Mountain Chocolate Factory to Participate in The Small Cap Showcase & WTR Insights Conference on June 9, 2026
3h ago